MXL– MaxLinear, Inc provides integrated, radio-frequency (RF) mixed-signal integrated circuits for broadband communications and data center and other network applications.

MXL – MaxLinear, Inc

Fundamentals Previously closed at 18.54
Day’s high 18.58
Day’s low 17.86
P/E ratio NA
EPS -0.82


Analysts opinion The business it is in, as a producer of Radio Frequency and mixed-signal circuits has a huge potential, with the trend of consumers’ demand for higher quality video streaming, and increased content online. MXL gained 10.9% in the last four weeks. It is expected to grow (EPS) at an exceptional 45.2%. The sell-side analysts have a 1.14 rating for the stock indicating a “Strong Buy”. Deere & Co boosted its stake in MXL by 0.7%, California State Teachers Retirement System increased its stake by 1.7%, American Century companies Inc., AlphaMark Advisors LLC and Numeric Investors LLC etc. acquired new stakes in MXL last quarter.
Technically, MXL is supposedly forming a second stage cup with handle base. It has support/resistance levels at $18.50 and $13.77. Insider Curtis Ling, the Chief Technical Officer sold 36,800 shares of the company on Tuesday at an average price of $18.02.
Sentiments Due to the news, the investor sentiments may be bullish for the stock.
Revenue Prediction Analysts are expecting the revenue to grow at 42% this next quarter and 32% for the year.
Social Media Pulse The stock has 55% higher chatter than usual.

CELG – Celgene Corporation, is a bio-pharmaceutical company, engaged in development and commercialization of therapies for treatment of cancer and inflammatory diseases through gene and protein regulation.

CELG – Celgene Corporation

Fundamentals Previously closed at 108.22
Day’s high 108.50
Day’s low 102.48
P/E ratio 55.86
EPS 1.94


Analyst opinion Analysts have a consensus 1.44 rating for the stock, which suggest a “Strong Buy”. The consensus target price for the stock is $145.84. The company has strong growth prospects.
Sentiments  Sentiments for the stock are bullish, post termination of merger of Pfizer and Allergan. There has been a lot of speculation regarding the subject, and given the fact that Allergan and Pfizer have been serial acquirers in healthcare, now that the merger is terminated it opens up a huge space for potential acquisitions. Investors are bullish on CELG due to it being a possible acquisition target for Allergan.
Social Media Pulse The stock has 100% higher social chatter than usual.


Disclaimer: This blog contains an aggregated view of analysts and opinions by the author. Do not consider this as financial advice. See


Leave a Reply

Your email address will not be published. Required fields are marked *